Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:RCUS
Previous Symbol
CUSIPN/A
Phone510-694-6200
Debt
Debt-to-Equity RatioN/A
Current Ratio15.97
Quick Ratio15.97
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares44,450,000
Market Cap$559.23 million
OptionableOptionable
Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions
What is Arcus Biosciences' stock symbol?
Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."
How were Arcus Biosciences' earnings last quarter?
Arcus Biosciences Inc (NYSE:RCUS) posted its quarterly earnings results on Thursday, November, 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.13. The company earned $4.29 million during the quarter, compared to the consensus estimate of $1.40 million. View Arcus Biosciences' Earnings History.
When is Arcus Biosciences' next earnings date?
What price target have analysts set for RCUS?
4 brokers have issued 12-month target prices for Arcus Biosciences' stock. Their forecasts range from $18.00 to $22.00. On average, they expect Arcus Biosciences' stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 57.5% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.
What is the consensus analysts' recommendation for Arcus Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.
Has Arcus Biosciences been receiving favorable news coverage?
Media headlines about RCUS stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcus Biosciences earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Are investors shorting Arcus Biosciences?
Arcus Biosciences saw a decrease in short interest during the month of November. As of November 15th, there was short interest totalling 945,455 shares, a decrease of 40.6% from the October 31st total of 1,590,795 shares. Based on an average daily volume of 274,697 shares, the short-interest ratio is currently 3.4 days. Approximately 4.0% of the shares of the stock are sold short. View Arcus Biosciences' Current Options Chain.
Who are some of Arcus Biosciences' key competitors?
Some companies that are related to Arcus Biosciences include Global Blood Therapeutics (GBT), Myokardia (MYOK), Xencor (XNCR), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), Endocyte (ECYT), Opko Health (OPK), AnaptysBio (ANAB), Pacira Pharmaceuticals (PCRX), Supernus Pharmaceuticals (SUPN), Reata Pharmaceuticals (RETA), Zogenix (ZGNX) and Innoviva (INVA).
Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the folowing people:
- Dr. Terry Rosen Ph.D., Co-Founder, CEO & Director (Age 58)
- Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 60)
- Ms. Jennifer Jarrett M.B.A., COO & CFO (Age 47)
- Mr. Steven Chan, VP of Fin., Corp. Controller & Principal Accounting Officer (Age 46)
- Dr. Stephen Young Ph.D., VP of Technology (Age 49)
When did Arcus Biosciences IPO?
(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.
Who are Arcus Biosciences' major shareholders?
Arcus Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Partner Fund Management L.P. (1.63%), JPMorgan Chase & Co. (1.06%), JPMorgan Chase & Co. (1.06%), Vanguard Group Inc. (1.02%), Vanguard Group Inc (1.02%) and Board of Trustees of The Leland Stanford Junior University (1.01%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.
Which institutional investors are selling Arcus Biosciences stock?
RCUS stock was sold by a variety of institutional investors in the last quarter, including Board of Trustees of The Leland Stanford Junior University, Partner Fund Management L.P., Virtus ETF Advisers LLC and Vident Investment Advisory LLC. View Insider Buying and Selling for Arcus Biosciences.
Which institutional investors are buying Arcus Biosciences stock?
RCUS stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., BlackRock Inc., Platinum Investment Management Ltd., MML Investors Services LLC, Marshall Wace LLP, Teachers Advisors LLC and Vanguard Group Inc. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.
How do I buy shares of Arcus Biosciences?
Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcus Biosciences' stock price today?
One share of RCUS stock can currently be purchased for approximately $12.54.
How big of a company is Arcus Biosciences?
Arcus Biosciences has a market capitalization of $559.23 million.
What is Arcus Biosciences' official website?
How can I contact Arcus Biosciences?
Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]
MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
